What is Wegovy 7.2mg?

Wegovy 7.2 mg is a newly developed higher dose from Novo Nordisk, the manufacturer of Wegovy. Clinical studies suggest it delivers weight-loss results comparable to the maximum dose of Mounjaro, with participants losing an average of around 21% of their body weight during treatment.

The 7.2 mg dose contains the same active ingredient, semaglutide, as the lower Wegovy doses, but at a higher strength. It works in the same way by mimicking the natural hormone GLP-1, which helps regulate appetite, slow gastric emptying, and support blood sugar control.

Initially, the 7.2 mg dose will be administered using three separate 2.4 mg injections per week. A single pre-filled pen designed specifically for the 7.2 mg dose is expected to become available in the future.

Until now, the highest approved Wegovy dose in the UK has been 2.4 mg once weekly. This higher dose option will allow suitable patients to further escalate their treatment where clinically appropriate, potentially supporting greater weight-loss outcomes.

As with all Wegovy doses, treatment at 7.2 mg is intended to be used as part of a comprehensive weight management programme, alongside dietary changes, increased physical activity, and ongoing support from healthcare professionals.

Key Takeaways

• Strong dose-response: Over 90% of patients lost at least 5% of body weight, with around one-third losing 25% or more.
• Greater weight loss at higher dose: Wegovy 7.2 mg achieved an average 21% weight loss over 72 weeks, outperforming the 2.4 mg dose and placebo.
• Well-tolerated safety profile: Side effects were mainly mild to moderate gastrointestinal symptoms, with only 3.3% discontinuing treatment due to adverse effects.

Summary of the STEP UP trial

• The 7.2 mg dose of Wegovy is more effective than the current highest 2.4 mg dose.
• Nearly half of participants lost 20% or more of their body weight over 72 weeks.
• Side effects were more frequent at the higher dose but were generally manageable.
• Wegovy 7.2 mg offers an option for patients who want to continue treatment after 2.4 mg to achieve further weight loss.

Who Can Take Wegovy 7.2 mg?

Wegovy 7.2 mg is intended for people who have already titrated up to 2.4 mg. You must be on the 2.4 mg dose for a minimum of 4 weeks before moving to the highest dose, as it contains the same active ingredient at a higher strength. A clinician’s approval and prescription are required before increasing to 7.2 mg.

If you’re new to Wegovy or weight-loss injections, you won’t begin at 7.2 mg. Your dose will be gradually increased over time, allowing your body to adjust and helping to minimise the risk of side effects. You will also need to meet specific BMI and health criteria to ensure the treatment is safe and appropriate:

• BMI of 30 or higher, or
• BMI of 27 or higher with a weight-related medical condition or risk factor (e.g., high blood pressure)

How It’s Administered

• The 7.2 mg dose currently comes as three separate 2.4 mg pens, requiring three injections per week.
• A single pre-filled pen for 7.2 mg will be available in the future.

What Does my Weight Loss Journey Look Like with Wegovy 7.2mg?

• If you’re already on Wegovy
  The 7.2 mg dose offers the option to increase your dose for potentially greater weight loss. If you’re happy with your current dose or already on a maintenance plan, there’s no need to switch—you can continue your journey at a level that works best for you.
• If you haven’t started Wegovy yet
  Wegovy 7.2 mg offers a more effective option, helping you achieve weight-loss results similar to Mounjaro, often at a more affordable cost.
• If you’re on a different treatment
  If you’re not currently using Wegovy, the 7.2 mg dose may be a reason to consider switching treatments. This higher dose can help you achieve results similar to Mounjaro, while often being a more cost-effective option.